OtherSeptember 28 at 06:31 PM

AstraZeneca (AZN LN) is to invest USD 2bln in Summit Therapeutics (SMMT) and collaborate on cancer drugs, according to WSJ

StockNow breaking-news AI analysis

AstraZeneca agreed to invest $2.0 billion in Summit Therapeutics convertible preferred stock and collaborate on oncology trials combining ivonescimab with sonesitatug vedotin and other portfolio therapies.

2 stocks

AZNAstraZeneca PLC$166.70Close

SMMTSummit Therapeutics Inc. Common Stock$18.24Close

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

U.S. Markets

Anthropic reported FY25 (USD) net loss  41.97 bln (prev. loss 8.3 bln Y/Y), revenue of 4.59 bln (prev.  386mln Y/Y), guides FY27 cloud and infrastructure spending at USD  518 bln

Geopolitics

US President Trump posts "Axios just released a story that “Trump” offered Sanctions Relief and Frozen Funds to Iran. This is untrue. I offered them NOTHING! Axios’ story, like most others, is a HOAX"